NASDAQ:SRRA - Sierra Oncology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.90 -0.02 (-1.04 %) (As of 03/20/2019 04:00 PM ET)Previous Close$1.92Today's Range$1.89 - $1.9352-Week Range$1.05 - $3.70Volume85,503 shsAverage Volume318,998 shsMarket Capitalization$141.49 millionP/E Ratio-2.53Dividend YieldN/ABeta1.8 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Receive SRRA News and Ratings via Email Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRRA Previous SymbolNASDAQ:DNAI CUSIPN/A CIK1290149 Webwww.sierraoncology.com Phone604-558-6536Debt Debt-to-Equity Ratio0.05 Current Ratio10.77 Quick Ratio10.77Price-To-Earnings Trailing P/E Ratio-2.53 Forward P/E Ratio-2.11 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book1.50Profitability EPS (Most Recent Fiscal Year)($0.75) Net Income$-53,330,000.00 Net MarginsN/A Return on Equity-47.10% Return on Assets-43.14%Miscellaneous EmployeesN/A Outstanding Shares74,470,000Market Cap$141.49 million Next Earnings Date5/9/2019 (Estimated) OptionableOptionable Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions What is Sierra Oncology's stock symbol? Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA." How were Sierra Oncology's earnings last quarter? Sierra Oncology Inc (NASDAQ:SRRA) posted its quarterly earnings data on Thursday, February, 28th. The biotechnology company reported ($0.19) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.01. View Sierra Oncology's Earnings History. When is Sierra Oncology's next earnings date? Sierra Oncology is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Sierra Oncology. What is the consensus analysts' recommendation for Sierra Oncology? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sierra Oncology. Has Sierra Oncology been receiving favorable news coverage? News stories about SRRA stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sierra Oncology earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near term. Who are some of Sierra Oncology's key competitors? Some companies that are related to Sierra Oncology include Forty Seven (FTSV), GlycoMimetics (GLYC), Prothena (PRTA), Arvinas (ARVN), Basilea Pharmaceutica (BPMUF), Dermira (DERM), NuCana (NCNA), ArQule (ARQL), Arcus Biosciences (RCUS), DiaMedica Therapeutics (DMCAF), Urogen Pharma (URGN), Assembly Biosciences (ASMB), Dynavax Technologies (DVAX), Kalvista Pharmaceuticals (KALV) and Zymeworks (ZYME). What other stocks do shareholders of Sierra Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sierra Oncology investors own include Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Global Blood Therapeutics (GBT), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Trevena (TRVN), Mallinckrodt (MNK), Viking Therapeutics (VKTX), ContraFect (CFRX) and TG Therapeutics (TGTX). Who are Sierra Oncology's key executives? Sierra Oncology's management team includes the folowing people: Dr. Nicholas R. Glover, Pres, CEO & Director (Age 50)Dr. Barbara Klencke, Chief Devel. Officer (Age 62)Dr. Mark M. Kowalski, Chief Medical Officer (Age 64)Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 45)Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 50) Who are Sierra Oncology's major shareholders? Sierra Oncology's stock is owned by many different of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (6.56%), Perceptive Advisors LLC (3.59%), Prosight Management LP (3.43%), 683 Capital Management LLC (2.92%), Dimensional Fund Advisors LP (1.36%) and Dimensional Fund Advisors LP (1.36%). View Institutional Ownership Trends for Sierra Oncology. Which institutional investors are selling Sierra Oncology stock? SRRA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Sphera Funds Management LTD., Perceptive Advisors LLC, Orbimed Advisors LLC, Prosight Management LP, Algert Global LLC, Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. View Insider Buying and Selling for Sierra Oncology. Which institutional investors are buying Sierra Oncology stock? SRRA stock was purchased by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, 683 Capital Management LLC, Hikari Power Ltd and Acadian Asset Management LLC. View Insider Buying and Selling for Sierra Oncology. How do I buy shares of Sierra Oncology? Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sierra Oncology's stock price today? One share of SRRA stock can currently be purchased for approximately $1.90. How big of a company is Sierra Oncology? Sierra Oncology has a market capitalization of $141.49 million. The biotechnology company earns $-53,330,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. What is Sierra Oncology's official website? The official website for Sierra Oncology is http://www.sierraoncology.com. How can I contact Sierra Oncology? Sierra Oncology's mailing address is 2150 -885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected] MarketBeat Community Rating for Sierra Oncology (NASDAQ SRRA)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 190 (Vote Outperform)Underperform Votes: 168 (Vote Underperform)Total Votes: 358MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe SRRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/20/2019 by MarketBeat.com StaffFeatured Article: What is the Consumer Price Index (CPI)?